Targeting the translation machinery in cancer

Virus-like particle-mediated intracellular delivery of mRNA cap analog with in vivo activity against hepatocellular carcinoma

(2015) Monika Zochowska et al.   Nanomedicine-Nanotechnology Biology and Medicine

Targeting TOR dependence in cancer

(2015)   Oncotarget

Targeting Translation Dependence in Cancer

(2015) Abba Malina et al.   Oncotarget

mTOR inhibitor efficacy is determined by the eIF4E/4E-BP ratio

(2015) Tommy Alain et al.   Oncotarget

Tumor suppression by small molecule inhibitors of translation initiation

(2015) Limo Chen et al.   Oncotarget

First Mnks degrading agents block phosphorylation of eIF4E, induce apoptosis, inhibit cell growth, migration and invasion in triple negative and Her2-overexpressing breast cancer cell lines

(2015) Senthilmurugan Ramalingam et al.   Oncotarget

The Scanning Mechanism of Eukaryotic Translation Initiation

(2014) Alan G. Hinnebusch   Annual Review of Biochemistry

Intrinsic and acquired resistance to MEK1/2 inhibitors in cancer

(2014) Matthew J. Sale et al.   BIOCHEMICAL SOCIETY TRANSACTIONS

Protein and Nucleotide Biosynthesis Are Coupled by a Single Rate-Limiting Enzyme, PRPS2, to Drive Cancer

(2014) John T. Cunningham et al.   CELL

MAP Kinase-Interacting Kinases—Emerging Targets against Cancer

(2014) Sarah Diab et al.   CHEMISTRY & BIOLOGY

Simplified Silvestrol Analogues with Potent Cytotoxic Activity

(2014) Bill C. Hawkins et al.   ChemMedChem

Discovery of 5-(2-(Phenylamino)pyrimidin-4-yl)thiazol-2(3H)-one Derivatives as Potent Mnk2 Inhibitors: Synthesis, SAR Analysis and Biological Evaluation

(2014) Sarah Diab et al.   ChemMedChem

The intra-tumor heterogeneity of cell signaling factors in breast cancer: p4E-BP1 and peIF4E are diffusely expressed and are real potential targets

(2014) S. Ramon y Cajal et al.   Clinical & Translational Oncology

Metformin and Cancer: Mounting Evidence Against an Association: Figure 1

(2014) Samy Suissa et al.   DIABETES CARE

Coupling 40S ribosome recruitment to modification of a cap-binding initiation factor by eIF3 subunit e

(2014) D. Walsh et al.   GENES & DEVELOPMENT

Proteomic analysis of cap-dependent translation identifies LARP1 as a key regulator of 5'TOP mRNA translation

(2014) J. Tcherkezian et al.   GENES & DEVELOPMENT

Decreased Expression of EIF4A1 After Preoperative Brachytherapy Predicts Better Tumor-Specific Survival in Cervical Cancer

(2014) Shanhui Liang et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

RNA G-quadruplexes cause eIF4A-dependent oncogene translation in cancer

(2014) Andrew L. Wolfe et al.   NATURE

eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies

(2014) Lise Boussemart et al.   NATURE

Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework

(2014) David Cook et al.   NATURE REVIEWS DRUG DISCOVERY

PI3K and cancer: lessons, challenges and opportunities

(2014) David A. Fruman et al.   NATURE REVIEWS DRUG DISCOVERY

Resistance to mTOR Kinase Inhibitors in Lymphoma Cells Lacking 4EBP1

(2014) Sharmila Mallya et al.   PLoS One

Phosphorylated Mnk1 and eIF4E Are Associated with Lymph Node Metastasis and Poor Prognosis of Nasopharyngeal Carcinoma

(2014) Jun Zheng et al.   PLoS One

Structure of the eukaryotic translation initiation factor eIF4E in complex with 4EGI-1 reveals an allosteric mechanism for dissociating eIF4G

(2014) E. Papadopoulos et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Oxygen sufficiency controls TOP mRNA translation via the TSC-Rheb-mTOR pathway in a 4E-BP-independent manner

(2014) Rachel Miloslavski et al.   Journal of Molecular Cell Biology

Evidence for a Functionally Relevant Rocaglamide Binding Site on the eIF4A–RNA Complex

(2013) Heather Sadlish et al.   ACS Chemical Biology

Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis

(2013) Denise A. Yardley et al.   ADVANCES IN THERAPY

On mTOR nomenclature

(2013) Michael N. Hall   BIOCHEMICAL SOCIETY TRANSACTIONS

Second-generation derivatives of the eukaryotic translation initiation inhibitor pateamine A targeting eIF4A as potential anticancer agents

(2013) Woon-Kai Low et al.   BIOORGANIC & MEDICINAL CHEMISTRY

mTORC1 Controls Mitochondrial Activity and Biogenesis through 4E-BP-Dependent Translational Regulation

(2013) Masahiro Morita et al.   Cell Metabolism

Rational Design of Resorcylic Acid Lactone Analogues as Covalent MNK1/2 Kinase Inhibitors by Tuning the Reactivity of an Enamide Michael Acceptor

(2013) Jin Xu et al.   ChemMedChem

Cap-Translation Inhibitor, 4EGI-1, Restores Sensitivity to ABT-737 Apoptosis through Cap-Dependent and -Independent Mechanisms in Chronic Lymphocytic Leukemia

(2013) S. Willimott et al.   CLINICAL CANCER RESEARCH

Rapamycin Resistance: mTORC1 Substrates Hold Some of the Answers

(2013) Sang-Oh Yoon et al.   CURRENT BIOLOGY

Growth control and ribosomopathies

(2013) Teng Teng et al.   CURRENT OPINION IN GENETICS & DEVELOPMENT

LARP1 specifically recognizes the 3′ terminus of poly(A) mRNA

(2013) Kazuma Aoki et al.   FEBS LETTERS

Control of oncogenesis by eIF2α phosphorylation: implications in PTEN and PI3K–Akt signaling and tumor treatment

(2013) Antonis E Koromilas et al.   Future Oncology

Post-transcriptional regulatory networks in immunity

(2013) Pavel Ivanov et al.   IMMUNOLOGICAL REVIEWS

Hypoxia-inducible Factor-1α (HIF-1α) Promotes Cap-dependent Translation of Selective mRNAs through Up-regulating Initiation Factor eIF4E1 in Breast Cancer Cells under Hypoxia Conditions

(2013) Tingfang Yi et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Adaptation to mTOR kinase inhibitors by amplification of eIF4E to maintain cap-dependent translation

(2013) Claire L. Cope et al.   JOURNAL OF CELL SCIENCE

Potential applications for biguanides in oncology

(2013) Michael Pollak   JOURNAL OF CLINICAL INVESTIGATION

Results of an International Randomized Phase III Trial of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus Versus Placebo to Control Metastatic Sarcomas in Patients After Benefit From Prior Chemotherapy

(2013) George D. Demetri et al.   JOURNAL OF CLINICAL ONCOLOGY

The eukaryotic translation initiation factor eIF4E is a direct transcriptional target of NF-κB and is aberrantly regulated in acute myeloid leukemia

(2013) F Hariri et al.   LEUKEMIA

Treatment of Breast and Lung Cancer Cells with a N-7 Benzyl Guanosine Monophosphate Tryptamine Phosphoramidate Pronucleotide (4Ei-1) Results in Chemosensitization to Gemcitabine and Induced eIF4E Proteasomal Degradation

(2013) Shui Li et al.   MOLECULAR PHARMACEUTICS

Protein synthesis rate is the predominant regulator of protein expression during differentiation

(2013) A. R. Kristensen et al.   Molecular Systems Biology

mTOR kinase structure, mechanism and regulation

(2013) Haijuan Yang et al.   NATURE

Targeting the unfolded protein response in disease

(2013) Claudio Hetz et al.   NATURE REVIEWS DRUG DISCOVERY

Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma

(2013) D. A. Krueger et al.   NEUROLOGY

Translation factors and ribosomal proteins control tumor onset and progression: how?

(2013) F Loreni et al.   ONCOGENE

Pancreatic tumours escape from translational control through 4E-BP1 loss

(2013) Y Martineau et al.   ONCOGENE

Sequential administration of methotrexate and asparaginase in relapsed or refractory pediatric acute myeloid leukemia

(2013) Jassada Buaboonnam et al.   PEDIATRIC BLOOD & CANCER

Human eIF4E promotes mRNA restructuring by stimulating eIF4A helicase activity

(2013) K. Feoktistova et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

mTORC1 Phosphorylation Sites Encode Their Sensitivity to Starvation and Rapamycin

(2013) S. A. Kang et al.   SCIENCE

Dynamic Recognition of the mRNA Cap by Saccharomyces cerevisiae eIF4E

(2013) Seán E. O’Leary et al.   STRUCTURE

Translation of viral mRNAs that do not require eIF4E is blocked by the inhibitor 4EGI-1

(2013) Natalia Redondo et al.   VIROLOGY

Modifying chemotherapy response by targeted inhibition of eukaryotic initiation factor 4A

(2013) R Cencic et al.   Blood Cancer Journal

Inhibition of PI3K/mTOR Leads to Adaptive Resistance in Matrix-Attached Cancer Cells

(2012) Taru Muranen et al.   CANCER CELL

Inhibition of RNA Polymerase I as a Therapeutic Strategy to Promote Cancer-Specific Activation of p53

(2012) Megan J. Bywater et al.   CANCER CELL

eIF4E/4E-BP Ratio Predicts the Efficacy of mTOR Targeted Therapies

(2012) T. Alain et al.   CANCER RESEARCH

mTOR Signaling in Growth Control and Disease

(2012) Mathieu Laplante et al.   CELL

Up-regulation of Translation Eukaryotic Initiation Factor 4E in Nucleophosmin 1 Haploinsufficient Cells Results in Changes in CCAAT Enhancer-binding Protein α Activity

(2012) Arati Khanna-Gupta et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Synthetic Silvestrol Analogues as Potent and Selective Protein Synthesis Inhibitors

(2012) Tao Liu et al.   JOURNAL OF MEDICINAL CHEMISTRY

Structure-Guided Design, Synthesis, and Evaluation of Guanine-Derived Inhibitors of the eIF4E mRNA–Cap Interaction

(2012) Xiaoqi Chen et al.   JOURNAL OF MEDICINAL CHEMISTRY

Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia

(2012) M R Janes et al.   LEUKEMIA

Cap-Dependent Translation Initiation Factor eIF4E: An Emerging Anticancer Drug Target

(2012) Yan Jia et al.   MEDICINAL RESEARCH REVIEWS

A unifying model for mTORC1-mediated regulation of mRNA translation

(2012) Carson C. Thoreen et al.   NATURE

The translational landscape of mTOR signalling steers cancer initiation and metastasis

(2012) Andrew C. Hsieh et al.   NATURE

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

(2012) Marco Gerlinger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Gemcitabine triggers a pro-survival response in pancreatic cancer cells through activation of the MNK2/eIF4E pathway

(2012) L Adesso et al.   ONCOGENE

MKNK1 is a YB-1 target gene responsible for imparting trastuzumab resistance and can be blocked by RSK inhibition

(2012) A Astanehe et al.   ONCOGENE

Anti-oncogenic potential of the eIF4E-binding proteins

(2012) Y Martineau et al.   ONCOGENE

Distinct perturbation of the translatome by the antidiabetic drug metformin

(2012) O. Larsson et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Rapamycin-Induced Insulin Resistance Is Mediated by mTORC2 Loss and Uncoupled from Longevity

(2012) D. W. Lamming et al.   SCIENCE

Emerging Therapeutics Targeting mRNA Translation

(2012) A. Malina et al.   Cold Spring Harbor Perspectives in Biology

Toward a Genome-Wide Landscape of Translational Control

(2012) O. Larsson et al.   Cold Spring Harbor Perspectives in Biology

Translational Control in Cancer Etiology

(2012) D. Ruggero   Cold Spring Harbor Perspectives in Biology

Tinkering with Translation: Protein Synthesis in Virus-Infected Cells

(2012) D. Walsh et al.   Cold Spring Harbor Perspectives in Biology

Regulation of mRNA Translation by Signaling Pathways

(2012) P. P. Roux et al.   Cold Spring Harbor Perspectives in Biology

Investigating Metformin for Cancer Prevention and Treatment: The End of the Beginning

(2012) Michael N. Pollak   Cancer Discovery

Targeting Synthetic Lethal Interactions between Myc and the eIF4F Complex Impedes Tumorigenesis

(2012) Chen-Ju Lin et al.   Cell Reports

Resistance to the Translation Initiation Inhibitor Silvestrol is Mediated by ABCB1/P-Glycoprotein Overexpression in Acute Lymphoblastic Leukemia Cells

(2011) Sneha V. Gupta et al.   AAPS Journal

Effects of hippuristanol, an inhibitor of eIF4A, on adult T-cell leukemia

(2011) Tomoyuki Tsumuraya et al.   BIOCHEMICAL PHARMACOLOGY

In vitro inhibition of translation initiation by N,N′-diarylureas—potential anti-cancer agents

(2011) Séverine Denoyelle et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Formation of the eIF4F Translation-Initiation Complex Determines Sensitivity to Anticancer Drugs Targeting the EGFR and HER2 Receptors

(2011) P. Zindy et al.   CANCER RESEARCH

Therapeutic Inhibition of MAP Kinase Interacting Kinase Blocks Eukaryotic Initiation Factor 4E Phosphorylation and Suppresses Outgrowth of Experimental Lung Metastases

(2011) B. W. Konicek et al.   CANCER RESEARCH

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

mTOR complex 2 signaling and functions

(2011) Won Jun Oh et al.   CELL CYCLE

A Phase 1 Dose Escalation, Pharmacokinetic, and Pharmacodynamic Evaluation of eIF-4E Antisense Oligonucleotide LY2275796 in Patients with Advanced Cancer

(2011) D. S. Hong et al.   CLINICAL CANCER RESEARCH

Down-regulation of PDCD4 expression is an independent predictor of poor prognosis in human renal cell carcinoma patients

(2011) Xiancheng Li et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Blocking eIF4E-eIF4G Interaction as a Strategy To Impair Coronavirus Replication

(2011) R. Cencic et al.   JOURNAL OF VIROLOGY

Activation and Function of the MAPKs and Their Substrates, the MAPK-Activated Protein Kinases

(2011) M. Cargnello et al.   MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS

Response to mTOR inhibition: activity of eIF4E predicts sensitivity in cell lines and acquired changes in eIF4E regulation in breast cancer

(2011) Sampoorna Satheesha et al.   Molecular Cancer

Global quantification of mammalian gene expression control

(2011) Björn Schwanhäusser et al.   NATURE

Chemical genetics identify eIF2α kinase heme-regulated inhibitor as an anticancer target

(2011) Ting Chen et al.   Nature Chemical Biology

Rapamycin passes the torch: a new generation of mTOR inhibitors

(2011) Don Benjamin et al.   NATURE REVIEWS DRUG DISCOVERY

Everolimus for Advanced Pancreatic Neuroendocrine Tumors

(2011) James C. Yao et al.   NEW ENGLAND JOURNAL OF MEDICINE

Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

(2011) José Baselga et al.   NEW ENGLAND JOURNAL OF MEDICINE

PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis

(2011) N. Ilic et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Phosphoproteomic Analysis Identifies Grb10 as an mTORC1 Substrate That Negatively Regulates Insulin Signaling

(2011) Y. Yu et al.   SCIENCE

The mTOR-Regulated Phosphoproteome Reveals a Mechanism of mTORC1-Mediated Inhibition of Growth Factor Signaling

(2011) P. P. Hsu et al.   SCIENCE

Selective Inhibition of a Regulatory Subunit of Protein Phosphatase 1 Restores Proteostasis

(2011) P. Tsaytler et al.   SCIENCE

Comparative Analysis of Proteome and Transcriptome Variation in Mouse

(2011) Anatole Ghazalpour et al.   PLoS Genetics

Ribosomal dysfunction and inherited marrow failure

(2010) Karthik A. Ganapathi et al.   BRITISH JOURNAL OF HAEMATOLOGY

Genetic Dissection of the Oncogenic mTOR Pathway Reveals Druggable Addiction to Translational Control via 4EBP-eIF4E

(2010) Andrew C. Hsieh et al.   CANCER CELL

Metformin Prevents Tobacco Carcinogen-Induced Lung Tumorigenesis

(2010) R. M. Memmott et al.   Cancer Prevention Research

Targeting RNA Polymerase I with an Oral Small Molecule CX-5461 Inhibits Ribosomal RNA Synthesis and Solid Tumor Growth

(2010) Denis Drygin et al.   CANCER RESEARCH

Not all substrates are treated equally: Implications for mTOR, rapamycin-resistance, and cancer therapy

(2010) Andrew Y. Choo et al.   CELL CYCLE

mTORC1 Directly Phosphorylates and Regulates Human MAF1

(2010) A. A. Michels et al.   MOLECULAR AND CELLULAR BIOLOGY

Over-expression of eukaryotic translation initiation factor 4 gamma 1 correlates with tumor progression and poor prognosis in nasopharyngeal carcinoma

(2010) Luxia Tu et al.   Molecular Cancer

Structure of the Human mTOR Complex I and Its Implications for Rapamycin Inhibition

(2010) Calvin K. Yip et al.   MOLECULAR CELL

A comprehensive map of the mTOR signaling network

(2010) Etienne Caron et al.   Molecular Systems Biology

Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor

(2010) Matthew R Janes et al.   NATURE MEDICINE

mTOR: from growth signal integration to cancer, diabetes and ageing

(2010) Roberto Zoncu et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression

(2010) L. Furic et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

mTORC1-Mediated Cell Proliferation, But Not Cell Growth, Controlled by the 4E-BPs

(2010) R. J. O. Dowling et al.   SCIENCE

Nontoxic Chemical Interdiction of the Epithelial-to-Mesenchymal Transition by Targeting Cap-Dependent Translation

(2009) Brahma Ghosh et al.   ACS Chemical Biology

Functional significance of eIF5A and its hypusine modification in eukaryotes

(2009) M. H. Park et al.   AMINO ACIDS

Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR)

(2009) Juan M. García-Martínez et al.   BIOCHEMICAL JOURNAL

Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin

(2009) S. Assouline et al.   BLOOD

Combined analysis of eIF4E and 4E-binding protein expression predicts breast cancer survival and estimates eIF4E activity

(2009) L J Coleman et al.   BRITISH JOURNAL OF CANCER

p53-Dependent Translational Control of Senescence and Transformation via 4E-BPs

(2009) Emmanuel Petroulakis et al.   CANCER CELL

c-Myc and eIF4F Constitute a Feedforward Loop That Regulates Cell Growth: Implications for Anticancer Therapy

(2009) C.-J. Lin et al.   CANCER RESEARCH

Inhibition of eIF2α Dephosphorylation Maximizes Bortezomib Efficiency and Eliminates Quiescent Multiple Myeloma Cells Surviving Proteasome Inhibitor Therapy

(2009) Denis M. Schewe et al.   CANCER RESEARCH

eIF4E Activation Is Commonly Elevated in Advanced Human Prostate Cancers and Significantly Related to Reduced Patient Survival

(2009) J. R. Graff et al.   CANCER RESEARCH

AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with In vitro and In vivo Antitumor Activity

(2009) C. M. Chresta et al.   CANCER RESEARCH

Regulation of Translation Initiation in Eukaryotes: Mechanisms and Biological Targets

(2009) Nahum Sonenberg et al.   CELL

Inhibition of Ovarian Cancer Growth by a Tumor-Targeting Peptide That Binds Eukaryotic Translation Initiation Factor 4E

(2009) S. Y. Ko et al.   CLINICAL CANCER RESEARCH

GCN2 Protein Kinase Is Required to Activate Amino Acid Deprivation Responses in Mice Treated with the Anti-cancer Agent l-Asparaginase

(2009) Piyawan Bunpo et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1

(2009) Carson C. Thoreen et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

(2009) Georg Hess et al.   JOURNAL OF CLINICAL ONCOLOGY

Potent in vitro and in vivo anticancer activities of des-methyl, des-amino pateamine A, a synthetic analogue of marine natural product pateamine A

(2009) G. Kuznetsov et al.   MOLECULAR CANCER THERAPEUTICS

Essential role for eIF4GI overexpression in the pathogenesis of inflammatory breast cancer

(2009) Deborah Silvera et al.   NATURE CELL BIOLOGY

Antitumor Activity and Mechanism of Action of the Cyclopenta[b]benzofuran, Silvestrol

(2009) Regina Cencic et al.   PLoS One

Genome-Wide Analysis in Vivo of Translation with Nucleotide Resolution Using Ribosome Profiling

(2009) N. T. Ingolia et al.   SCIENCE

Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2

(2009) Morris E Feldman et al.   PLOS BIOLOGY

c-Myc and eIF4F Are Components of a Feedforward Loop that Links Transcription and Translation

(2008) C.-J. Lin et al.   CANCER RESEARCH

Metformin attenuates the stimulatory effect of a high-energy diet on in vivo LLC1 carcinoma growth

(2008) C. Algire et al.   ENDOCRINE-RELATED CANCER

The Mnks: MAP kinase-interacting kinases (MAP kinase signal-integrating kinases)

(2008) Maria Buxade   Frontiers in Bioscience-Landmark

eIF4GI links nutrient sensing by mTOR to cell proliferation and inhibition of autophagy

(2008) Francisco Ramírez-Valle et al.   JOURNAL OF CELL BIOLOGY

PDCD4gene silencing in gliomas is associated with 5′CpG island methylation and unfavourable prognosis

(2008) Fei Gao et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

(2008) Robert J Motzer et al.   LANCET

Stability of Eukaryotic Translation Initiation Factor 4E mRNA Is Regulated by HuR, and This Activity Is Dysregulated in Cancer

(2008) I. Topisirovic et al.   MOLECULAR AND CELLULAR BIOLOGY

Requirement of RNA Binding of Mammalian Eukaryotic Translation Initiation Factor 4GI (eIF4GI) for Efficient Interaction of eIF4E with the mRNA Cap

(2008) A. Yanagiya et al.   MOLECULAR AND CELLULAR BIOLOGY

Translational control of the innate immune response through IRF-7

(2008) Rodney Colina et al.   NATURE

Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or Lymphangioleiomyomatosis

(2008) John J. Bissler et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation

(2008) A. Y. Choo et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

RNA polymerases I and III, non-coding RNAs and cancer

(2008) Robert J. White   TRENDS IN GENETICS

Mechanisms of Disease: survival benefit of temsirolimus validates a role for mTOR in the management of advanced RCC

(2008) Robert A Figlin   Nature clinical practice. Oncology